Kara E Rudolph
Overview
Explore the profile of Kara E Rudolph including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu H, Li F, Lesko C, Fink D, Rudolph K, Harhay M, et al.
Int J Epidemiol
. 2025 Jan;
54(1).
PMID: 39868475
Observational studies play an increasingly important role in estimating causal effects of a treatment or an exposure, especially with the growing availability of routinely collected real-world data. To facilitate drawing...
2.
Doonan S, Wheeler-Martin K, Davis C, Mauro C, Bruzelius E, Crystal S, et al.
Int J Drug Policy
. 2025 Jan;
137:104713.
PMID: 39847857
Background: Identifying the most effective state laws and provisions to reduce opioid overdose deaths remains critical. Methods: Using expert ratings of opioid laws, we developed annual state scores for three...
3.
Martins S, Bruzelius E, Mauro C, Santaella-Tenorio J, Boustead A, Wheeler-Martin K, et al.
Int J Drug Policy
. 2025 Jan;
136:104687.
PMID: 39793270
Background: Wider availability of cannabis through medical and recreational legalization (MCL alone and RCL+MCL) has been hypothesized to contribute to reductions in opioid use, misuse, and related harms. We examined...
4.
Schraw J, Rudolph K, Gribble M
Environ Epidemiol
. 2024 Oct;
8(6):e347.
PMID: 39399734
No abstract available.
5.
Ross R, Inose S, Shulman M, Nunes E, Zalla L, Burlew A, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2436612.
PMID: 39365581
Importance: Racial and ethnic disparities in access to treatment and quality of treatment for opioid use disorder (OUD) have been identified in usual care settings. In contrast, disparities in treatment...
6.
Mannes Z, Nowels M, Mauro C, Cook S, Wheeler-Martin K, Gutkind S, et al.
J Gen Intern Med
. 2024 Oct;
PMID: 39354252
Background: U.S. state electronic prescription drug monitoring programs (PDMPs) are associated with reduced opioid dispensing among people with chronic pain and may impact use of other chronic pain treatments. In...
7.
8.
Ross R, Rudolph K, Shover C
Addiction
. 2024 Aug;
119(12):2211-2215.
PMID: 39149781
Background And Aims: Extended release buprenorphine injection (INJ-BUP) has been available in the United States since 2018. INJ-BUP has the potential to positively impact opioid use disorder (OUD) treatment outcomes...
9.
Hoffman K, Salazar-Barreto D, Williams N, Rudolph K, Diaz I
Epidemiology
. 2024 Aug;
35(5):667-675.
PMID: 39109818
This tutorial discusses a methodology for causal inference using longitudinal modified treatment policies. This method facilitates the mathematical formalization, identification, and estimation of many novel parameters and mathematically generalizes many...
10.
Ross R, Nunes E, Olfson M, Shulman M, Krawczyk N, Stuart E, et al.
Addiction
. 2024 Aug;
119(11):1975-1986.
PMID: 39099417
Background And Aims: Extended-release naltrexone (XR-NTX) and sublingual buprenorphine (SL-BUP) are both approved for opioid use disorder (OUD) treatment in any medical setting. We aimed to compare the real-world effectiveness...